RA Cap­i­tal-backed cell ther­a­py play­er in the neoanti­gen game grabs a $121M megaround to fund first hu­man stud­ies

There’s more than 1 way to skin a mouse. And any­one who fig­ures out the best way in on­col­o­gy can open the door to a valu­able new plat­form tech­nol­o­gy.

Un­daunt­ed by the pi­o­neers who have gone ahead in per­son­al­ized neoanti­gen R&D work, the team at Achilles Ther­a­peu­tics op­er­at­ing out of Steve­nage in the UK be­lieve they have found a bet­ter ther­a­peu­tic ap­proach  — start­ing with non-small cell lung can­cer and in melanoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER